###begin article-title 0
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 124 131 124 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
TCF7L2 gene polymorphisms do not predict susceptibility to diabetes in tropical calcific pancreatitis but may interact with SPINK1 and CTSB mutations in predicting diabetes
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 398 405 398 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 467 474 467 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 603 610 603 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 628 635 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 644 649 644 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
Tropical calcific pancreatitis (TCP) is a type of chronic pancreatitis unique to developing countries in tropical regions and one of its important features is invariable progression to diabetes, a condition called fibro-calculous pancreatic diabetes (FCPD), but the nature of diabetes in TCP is controversial. We analysed the recently reported type 2 diabetes (T2D) associated polymorphisms in the TCF7L2 gene using a case-control approach, under the hypothesis that TCF7L2 variants should show similar association if diabetes in FCPD is similar to T2D. We also investigated the interaction between the TCF7L2 variants and N34S SPINK1 and L26V CTSB mutations, since they are strong predictors of risk for TCP.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 551 558 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 567 572 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 670 677 670 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
Two polymorphisms rs7903146 and rs12255372 in the TCF7L2 gene were analyzed by direct sequencing in 478 well-characterized TCP patients and 661 healthy controls of Dravidian and Indo-European ethnicities. Their association with TCP with diabetes (FCPD) and without diabetes was tested in both populations independently using chi-square test. Finally, a meta analysis was performed on all the cases and controls for assessing the overall significance irrespective of ethnicity. We dichotomized the whole cohort based on the presence or absence of N34S SPINK1 and L26V CTSB mutations and further subdivided them into TCP and FCPD patients and compared the distribution of TCF7L2 variants between them.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 320 327 320 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 455 462 455 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
The allelic and genotypic frequencies for both TCF7L2 polymorphisms, did not differ significantly between TCP patients and controls belonging to either of the ethnic groups or taken together. No statistically significant association of the SNPs was observed with TCP or FCPD or between carriers and non-carriers of N34S SPINK1 and L26V CTSB mutations. The minor allele frequency for rs7903146 was different between TCP and FCPD patients carrying the N34S SPINK1 variant but did not reach statistical significance (OR = 1.59, 95% CI = 0.93-2.70, P = 0.09), while, TCF7L2variant showed a statistically significant association between TCP and FCPD patients carrying the 26V allele (OR = 1.69, 95% CI = 1.11-2.56, P = 0.013).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 266 273 266 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 290 297 290 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 301 306 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
Type 2 diabetes associated TCF7L2 variants are not associated with diabetes in TCP. Since, TCF7L2 is a major susceptibility gene for T2D, it may be hypothesized that the diabetes in TCP patients may not be similar to T2D. Our data also suggests that co-existence of TCF7L2 variants and the SPINK1 and CTSB mutations, that predict susceptibility to exocrine damage, may interact to determine the onset of diabetes in TCP patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 517 518 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 519 520 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1049 1050 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1085 1086 1085 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1116 1117 1116 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1418 1419 1418 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1420 1422 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
###xml 1127 1135 <span type="species:ncbi:9606">patients</span>
###xml 1195 1203 <span type="species:ncbi:9606">patients</span>
###xml 1324 1332 <span type="species:ncbi:9606">patients</span>
###xml 1385 1393 <span type="species:ncbi:9606">patients</span>
Pancreatitis is generally believed to be a disease where pancreas is injured by enzymes that are normally secreted by the acinar cells. Chronic Pancreatitis (CP) is a continuing or relapsing inflammatory process of pancreas leading to exocrine and/or endocrine insufficiency. Tropical calcific pancreatitis (TCP) is a type of CP unique to developing countries in tropical region [1]. An important feature of TCP is its consistent progression to diabetes, commonly known as fibro-calculous pancreatic diabetes (FCPD) [1,2]. FCPD is thought to be a type of diabetes secondary to TCP, resulting from destruction of beta-cell mass in the pancreas [3]. However, several studies have shown partial preservation of beta-cell mass [3] and evidence of insulin resistance to a similar degree as seen in type 2 diabetes (T2D) patients [4], suggesting that the diabetes in FCPD could be type T2D, while others have not found insulin resistance to be a major factor in FCPD [5]. It was believed earlier that diabetes specific complications do not occur in FCPD [6], but prevalence of retinopathy, [7] nephropathy and neuropathy [8] in FCPD patients has been reported to be no different from matched group of patients with T2D. Similarly, although the diabetes is severe and insulin requiring in both FCPD and type 1 diabetes (T1D), FCPD patients rarely develop ketoacidosis, in contrast to the T1D patients, who are ketosis prone [9,10].
###end p 11
###begin p 12
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1</italic>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB</italic>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTRC</italic>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 990 997 990 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1230 1237 1230 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1243 1245 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1313 1320 1313 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1583 1591 <span type="species:ncbi:9606">patients</span>
Mutations in the serine protease inhibitor, Kazal type 1 (SPINK1) [11-15], cystic fibrosis transmembrane regulator (CFTR) [16], cathepsin B (CTSB) [17] and recently, chymotrypsin C (CTRC) [18] genes have been identified to be associated with TCP but they mostly associate with pancreatic exocrine dysfunction. No study has yet investigated the genetic basis of diabetes in TCP and FCPD. Based on the suggestive linkage of T2D to chromosome 10q, a microsatellite, DG10S478, within intron 3 of transcription factor 7-like 2 (TCF7L2) gene was found to be strongly associated with T2D [19]. An association of a variant of the gene, rs7903146 along with other SNPs in linkage disequilibrium with this polymorphism was first reported in Islandic, Danish and in the US cohort [19]. Subsequently this association was replicated in other populations like Indian [20,21], French [22], U.K [23] and Finnish populations [24], and these variants account for the highest T2D risk confirmed to date [25]. TCF7L2 gene variants have also been proposed to play important role in T1D because of its effects on blood glucose homeostasis [26]; however a recent study failed to find any association and age-of-onset effect of T1D with rs7903146 SNP in TCF7L2 gene [27]. This suggested that a T2D mechanism mediated by polymorphisms in TCF7L2 does not participate in the etiology of T1D, thus susceptibility factors for T2D could be different from those involved in T1D. Hence, investigating a known susceptibility factor for T1D or T2D can help in understanding the type and mechanism of diabetes in FCPD patients.
###end p 12
###begin p 13
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 269 276 269 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 379 386 379 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 624 631 624 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 649 656 649 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 665 670 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 713 720 713 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
As the type of diabetes in FCPD is not clearly understood, we used association of TCF7L2 variants with T2D as a marker to decipher the type of diabetes in FCPD. Since there are suggestions that TCP is the pre-diabetic stage of FCPD, we also analyzed the association of TCF7L2 polymorphisms in TCP patients. We hypothesized that we would observe an association of variants in the TCF7L2 gene with FCPD, if diabetes in these patients is T2D. Since diabetes in TCP is also thought to be due to destruction of endocrine pancreatic cells secondary to destruction of exocrine pancreas, we investigated the interaction between the TCF7L2 variants and N34S SPINK1 and L26V CTSB mutations and explored whether presence of TCF7L2 variants in patients with these mutations predisposes them to FCPD.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 15
###begin p 16
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 745 750 <span type="species:ncbi:9606">human</span>
478 unrelated individuals (320 males and 158 females) were diagnosed as TCP (n = 286) or FCPD (n = 192) patients based on the established WHO criteria [28]. Of these, 333 patients were of Dravidian ethnicity and 145 belonged to Indo-European ethnicity. Six hundred and sixty one age matched individuals (332 males and 329 females) comprising of 259 Dravidians and 402 Indo-Europeans without any complaints and evidence of pancreatitis were included as controls [17,20]. Both patients and the controls filled a detailed questionnaire and signed a written informed consent for genetic analysis. The Institutional Ethics Committee of all the institutes approved the study following the Indian Council of Medical Research guidelines for research on human subjects.
###end p 16
###begin title 17
Genetic analysis
###end title 17
###begin p 18
###xml 119 126 119 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 636 641 <span type="species:ncbi:42554">tetra</span>
Genomic DNA from all the patients and healthy volunteers were utilized for this study. Primers, amplifying segments of TCF7L2 gene harboring SNPs rs7903146 and rs12255372 were adopted from our earlier study [20]. PCR products were purified and sequenced individually on both the strands using Big-dye terminator cycle sequencing ready kit (Applied Biosystems, Foster City, CA) on an ABI3730 Genetic Analyzer (Applied Biosystems Foster City, CA). In case of unclear sequence data, we repeated direct sequencing under various conditions until the genotype was determined correctly. Ten percent of the genotyping results were validated on tetra primer based analysis for the 2 SNPs [20] and no discrepancy was observed.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 864 871 864 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 880 885 880 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 982 989 982 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1347 1349 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
###xml 1158 1166 <span type="species:ncbi:9606">patients</span>
The allele and genotype frequencies were calculated for the SNPs (table 1) in cohorts of both ethnicities separately as well as together and to analyze deviation from the Hardy-Weinberg equilibrium, observed and expected genotype frequencies were compared by Markov simulation based goodness of fit test [29]. Chi-square test was used to analyze the statistical significance of the difference in allelic distribution of various polymorphisms in patients and controls (DeFinitte; ). For assessing the overall significance irrespective of ethnicities, the meta-analysis statistic was used and the forest plots were generated under the fixed effect model using Comprehensive Meta Analysis  software version 2.2.046 and the Q test was used to test for homogeneity of groupings [30]. The whole cohort was dichotomized initially based on the presence or absence of N34S SPINK1 and L26V CTSB mutations and then the two groups were subdivided into TCP and FCPD patients and distribution of TCF7L2 variants was compared between them. Unless indicated specifically, a p-value of 0.05 was considered significant in all the analyses. This study with random selection of patients and controls has 80% power to detect an effect with an OR as low as 1.3 at alpha = 0.05 and 95% power at the OR of 1.46, which was identified in our earlier study on T2D subjects [20].
###end p 20
###begin p 21
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Allelic and genotypic frequencies for the TCF7L2 variants in TCP patients and controls of different ethnic groups
###end p 21
###begin p 22
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&amp;</sup>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">@</sup>
SNP, single nucleotide polymorphism; n, number of individuals; &, Chromosome position according to National Centre for Biotechnology Information (NCBI), Build 36.2, contig accession number NT 030059.12; @, values in the parentheses indicate percentage genotype frequency
###end p 22
###begin title 23
Results and discussion
###end title 23
###begin p 24
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 403 404 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1125 1132 1125 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1194 1201 1194 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1219 1226 1219 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 1230 1235 1230 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 1085 1093 <span type="species:ncbi:9606">patients</span>
###xml 1263 1271 <span type="species:ncbi:9606">patients</span>
The two polymorphisms rs7903146 and rs12255372 in the TCF7L2 gene, reported to be most strongly associated with T2D, were analyzed in a cohort of TCP and FCPD patients and controls belonging to Dravidian and Indo-European ethnicities. It is believed by most workers in the field that FCPD is the logical end point of TCP and enough evidence exists to suggest that TCP is the pre-diabetic stage of FCPD [3]. Thus, we also analyzed the association of TCF7L2 variants in the entire cohort irrespective of their diabetic status. In addition, clinical presentation is known to be variable for FCPD [1,2]. Most of the patients present with pain abdomen and evidence of pancreatitis and subsequently develop diabetes at a later stage; a small proportion present with diabetes and are detected to have pancreatic stones and calcification on subsequent investigations [1,2]. It may be surmised that additional diabetes susceptibility gene may account for the earlier phenotype of diabetes. Hence, an attempt was also made to dichotomize the cohort into TCP and FCPD to investigate whether FCPD patients have an additional risk due to TCF7L2 polymorphisms. We also investigated whether co-inheritance of TCF7L2 variants with the SPINK1 and CTSB mutations predisposes these patients to develop diabetes.
###end p 24
###begin p 25
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 493 500 493 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 725 732 725 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1077 1084 1077 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1115 1116 1115 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
###xml 932 940 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 1007 1015 <span type="species:ncbi:9606">patients</span>
Both the polymorphisms followed Hardy-Weinberg equilibrium (p > 0.05) and on comparing the allele frequencies within the ethnic groups, Dravidian patients vs Dravidian controls and Indo-European patients vs Indo-European controls, no significant differences were seen (table 1), neither did the genotype relative risk differ significantly between patients and controls (table 2). A meta-analysis of all cases and control subjects from both ethnicities, showed similar results for both SNPs in TCF7L2 gene [(95%CI, 0.95-1.16; P = 0.63, Cochran's Q = 0.0092, P = 0.92 for rs7903146) and (95%CI, 1.01-1.29; P = 0.92, Cochran's Q = 0.0482, P = 0.83 for rs12255372)] (fig 1). In order to explore the possibility of association of TCF7L2 variants with FCPD, the analysis was carried out in TCP patients with diabetes (FCPD) and those without diabetes separately. Allele and genotypic frequencies did not differ significantly, between TCP patients and controls, FCPD patients and controls and between TCP and FCPD patients, suggesting lack of statistically significant association of TCF7L2 polymorphisms with FCPD (table 3).
###end p 25
###begin p 26
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
Estimates of the genotype and allele relative risks for the TCF7L2 variants in the cases and controls based on ethnicity
###end p 26
###begin p 27
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&amp;</sup>
SNP, single nucleotide polymorphism; *baseline genotype at rs7903146-CC, rs12255372-GG; Het OR & Hom OR, genotype relative risk (GRR) for heterozygotes and homozygotes respectively (GRR was calculated by comparing with the baseline genotype); &, allelic OR; P, P value; DR, Dravidians; IE, Indo-European
###end p 27
###begin p 28
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
Estimates of the genotype and allele relative risks for the TCF7L2 variants in the cases and controls based on clinical diagnosis
###end p 28
###begin p 29
###xml 323 324 323 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&amp;</sup>
SNP, single nucleotide polymorphism; TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; *baseline genotype at rs7903146-CC, rs12255372-GG; Het OR & Hom OR, genotype relative risk (GRR) for heterozygotes and homozygotes respectively (GRR was calculated by comparing with the baseline genotype); &, allelic OR; P, P value
###end p 29
###begin p 30
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Meta-analysis for association of TCF7L2 variants with TCP</bold>
Meta-analysis for association of TCF7L2 variants with TCP. Forest plot showing results of meta analysis. Odds ratio for each study is represented by a block bounded by its confidence interval; Combined effect for the two studies has been calculated using fixed effect model; A, rs7903146; B, rs12255372.
###end p 30
###begin p 31
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 432 439 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 856 863 856 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 925 932 925 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
###xml 1058 1066 <span type="species:ncbi:9606">patients</span>
Association analysis of the total cohort after dichotomization based on N34S SPINK1 and L26V CTSB mutation status showed comparable allele and genotype frequencies for rs7903146 in both groups, indicating that co-existence of these variants does not increase the risk of developing diabetes in these patients (table 4). However, the minor allele frequency for rs7903146 was different between TCP and FCPD patients carrying the N34S SPINK1 variant but did not reach statistical significance (OR = 1.59, 95% CI = 0.93-2.70, P = 0.09). Interestingly, similar analysis using L26V CTSB variant showed a statistically significant association between TCP and FCPD patients carrying the mutant allele compared to those without the variant (OR = 1.69, 95% CI = 1.11-2.56, P = 0.013) (table 4). Similar results were obtained on analysis of the rs12255372 variant in TCF7L2 gene (data not presented). This suggests that co-existence of TCF7L2 variants and the variants predicting susceptibility to exocrine damage may interact to determine the onset of diabetes in TCP patients. However, this may need to be replicated in larger sample size since there is a possibility of a chance association due to small sample size.
###end p 31
###begin p 32
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 66 73 <span type="species:ncbi:9606">patient</span>
Association of TCF7L2 variant rs7903146 on dichotomization of the patient cohort based on N34S SPINK1 and L26V CTSB mutation status
###end p 32
###begin p 33
TCP, tropical calcific pancreatitis; FCPD, fibro-calculous pancreatic diabetes; MAF, Minor allele frequency; OR, odds ratio; CI, confidence interval; P, p value;
###end p 33
###begin p 34
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 457 464 457 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 849 856 849 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 915 917 915 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 943 950 943 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1077 1079 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1156 1162 1156 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1189 1196 1189 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1276 1283 1276 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 1421 1427 1421 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 1509 1517 <span type="species:ncbi:9606">patients</span>
We and others have earlier replicated the strong association of TCF7L2 variants with T2D in Indian population and provided evidence of its likely role in the pathogenesis of T2D by influencing both insulin secretion and insulin resistance [20]. According to accelerator hypothesis, T1D and T2D may share a common etiology of hyperglycemia-induced beta cell damage but T1D may have the added effects of autoimmunity [31]. However, the lack of association of TCF7L2 with T1D, as shown by Field et al., does not support the model of a shared major causal pathway in T2D and T1D [32]. Hence the genes that determine susceptibility to T1D must be different from the susceptibility genes of T2D. This has important implications for diabetes in TCP since overlapping features of T1D and T2D are observed in FCPD. As the overall evidence for association of TCF7L2 gene variants exceeds genome-wide significance criteria (10-5) and clearly establishes TCF7L2 as a T2D susceptibility gene of substantial importance in majority of populations world-wide [33] including Indian population [20], it is less likely that T2D may have a susceptibility factor stronger than TCF7L2. A lack of association of TCF7L2 with TCP or FCPD observed in our study, may suggest a role for genes other than TCF7L2 to be predictive of susceptibility to T2D. Since there is debate about the type of diabetes in TCP and FCPD, the lack of association with TCF7L2, the gene most strongly associated with T2D may suggest that the diabetes in TCP patients does not have similar features as T2D.
###end p 34
###begin title 35
Conclusion
###end title 35
###begin p 36
###xml 3 10 3 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 159 166 159 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 307 314 307 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 477 484 477 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
###xml 553 560 553 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SPINK1 </italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
As TCF7L2 is a major susceptibility gene for T2D, a lack of association of TCF7L2 variants with TCP or FCPD observed in our study suggests that T2D associated TCF7L2 variants are not associated with diabetes in TCP or the diabetes in TCP patients may not be similar to T2D. Thus, although the variations in TCF7L2 increase the risk for T2D and may affect insulin secretion, they do not alter susceptibility to FCPD, the diabetes in TCP patients. However, co-inheritance of the TCF7L2 variants with the pancreatitis associated susceptibility variants in SPINK1 and CTSB genes may predict the development of diabetes in these patients, but these observations need to be confirmed independently.
###end p 36
###begin title 37
Competing interests
###end title 37
###begin p 38
The authors declare that they have no competing interests.
###end p 38
###begin title 39
Authors' contributions
###end title 39
###begin p 40
###xml 224 232 <span type="species:ncbi:9606">patients</span>
SM did all the genotyping, statistical analysis and wrote the first draft of the manuscript. SB and SP assisted in the genotyping and statistical analysis whereas DNR, GVR, SPS and VT were involved in the recruitment of the patients and controls. GRC conceptualized the study, supervised the results and finalized the manuscript. All the authors have gone through the manuscript and have consented to the final manuscript.
###end p 40
###begin title 41
Pre-publication history
###end title 41
###begin p 42
The pre-publication history for this paper can be accessed here:
###end p 42
###begin p 43

###end p 43
###begin title 44
Acknowledgements
###end title 44
###begin p 45
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
The authors express their gratitude to all the patients and the normal individuals for voluntarily participating in the study and especially for giving informed consent for genetic studies. The help of Dr A Ramakrishna, Asian Institute of Gastroenterology, Hyderabad in recruitment of patients and collection of blood samples and Mr Charles J Spurgeon, CCMB, Hyderabad in genotyping is gratefully acknowledged. The study was conducted with the financial support of Council of Scientific and Industrial Research, Ministry of Science and Technology, Government of India (NWP0032).
###end p 45
###begin article-title 46
Tropical chronic pancreatitis
###end article-title 46
###begin article-title 47
Tropical pancreatitis. The Indian Experience
###end article-title 47
###begin article-title 48
Pancreatic beta cell function in tropical pancreatic diabetes
###end article-title 48
###begin article-title 49
Insulin resistance in fibrocalculous (tropical) pancreatic diabetes
###end article-title 49
###begin article-title 50
Beta cell function and insulin sensitivity in tropical calcific pancreatitis from North India
###end article-title 50
###begin article-title 51
Clinical and hormonal aspects of pancreatic diabetes
###end article-title 51
###begin article-title 52
Retinopathy in tropical pancreatic diabetes
###end article-title 52
###begin article-title 53
Peripheral neuropathy in tropical pancreatic diabetes
###end article-title 53
###begin article-title 54
The ketosis resistance in Fibrocalculous Pancreatic Diabetes 1. Clinical observations and endocrine metabolic measurements during oral glucose tolerance test
###end article-title 54
###begin article-title 55
Tropical pancreatic diabetes in South India: heterogeneity in clinical and biochemical profile
###end article-title 55
###begin article-title 56
Mutations in the pancreatic secretory trypsin inhibitor gene (PSTI/SPINK1) rather than the cationic trypsinogen gene (PRSS1) are significantly associated with tropical calcific pancreatitis
###end article-title 56
###begin article-title 57
Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations
###end article-title 57
###begin article-title 58
SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Indian subcontinent
###end article-title 58
###begin article-title 59
SPINK1/PSTI mutations are associated with tropical pancreatitis in Bangladesh. A preliminary report
###end article-title 59
###begin article-title 60
SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh
###end article-title 60
###begin article-title 61
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Mutations in the cystic fibrosis transmembrane regulator gene in patients with tropical calcific pancreatitis
###end article-title 61
###begin article-title 62
Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis
###end article-title 62
###begin article-title 63
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis
###end article-title 63
###begin article-title 64
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
###end article-title 64
###begin article-title 65
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population
###end article-title 65
###begin article-title 66
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians
###end article-title 66
###begin article-title 67
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
Transcription factor TCF7L2 genetic study in French population
###end article-title 67
###begin article-title 68
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk
###end article-title 68
###begin article-title 69
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample
###end article-title 69
###begin article-title 70
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
The importance of TCF7L2
###end article-title 70
###begin article-title 71
TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta
###end article-title 71
###begin article-title 72
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2 </italic>
The TCF7L2 locus and type 1 diabetes
###end article-title 72
###begin article-title 73
Score tests for association between traits and haplotypes when linkage phase is ambiguous
###end article-title 73
###begin article-title 74
Some methods for strengthening the common chi2 tests
###end article-title 74
###begin article-title 75
The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes
###end article-title 75
###begin article-title 76
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects
###end article-title 76
###begin article-title 77
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCF7L2</italic>
###xml 112 117 <span type="species:ncbi:9606">Women</span>
###xml 122 125 <span type="species:ncbi:9606">Men</span>
Variant of Transcription Factor 7-Like 2 (TCF7L2) Gene and the Risk of Type 2 Diabetes in Large Cohorts of U.S. Women and Men
###end article-title 77

